This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kistler, J. P. Articles by Oertel, L. B. Search for Related Content PubMed PubMed Citation Articles by Kistler, J. P. Articles by Oertel, L. B.

Stroke, Vol 24, 1360-1365, Copyright © 1993 by American Heart Association

ARTICLES

Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. BAATAF Investigators

JP Kistler, DE Singer, MM Millenson, KA Bauer, DR Gress, S Barzegar, RA Hughes, MA Sheehan, SW Maraventano and LB Oertel
Neurology/Stroke Service, Massachusetts General Hospital, Boston 02114.

BACKGROUND AND PURPOSE: The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) demonstrated that low-intensity warfarin anticoagulation can, with safety, sharply reduce the rate of stroke in patients with nonvalvular atrial fibrillation. The beneficial effect of warfarin was presumably related to a decrease in clot formation in the cardiac atria and subsequent embolization. METHODS: To assess the effect of warfarin therapy on in vivo clotting in patients in the BAATAF, we measured the plasma level of prothrombin activation fragment F1+2. One sample was obtained from 125 patients from the BAATAF; 62 were taking warfarin and 63 were not taking warfarin (control group). RESULTS: The warfarin group had a 71% lower mean F1+2 level than the control group (mean F1+2 of 1.57 nmol/L in the control group compared with a mean of 0.46 nmol/L in the warfarin group; P < .001). F1+2 levels were higher in older subjects but were consistently lower in the warfarin group at all ages. Fifty-two percent of patients in the control group were taking chronic aspirin therapy at the time their F1+2 level was measured. Control patients taking aspirin had F1+2 levels very similar to control patients not taking aspirin (mean of 1.52 nmol/L for control patients on aspirin compared with 1.64 nmol/L for control patients off aspirin; P > .1). CONCLUSIONS: We conclude that prothrombin activation was significantly suppressed in vivo by warfarin but not aspirin among patients in the BAATAF. These findings correlate with the marked reduction in ischemic stroke noted among patients in the warfarin treatment group observed in the BAATAF.

This article has been cited by other articles:

				K. L. Furie, R. Rosenberg, J. L. Thompson, K. Bauer, J. P. Mohr, B. Rosner, R. Sciacca, S. Barzegar, B. Thornell, T. Costigan, et al. Thrombin generation in non-cardioembolic stroke subtypes: The Hemostatic System Activation Study Neurology, September 14, 2004; 63(5): 777 - 784. [Abstract] [Full Text] [PDF]

				H. Inoue, T. Nozawa, K. Okumura, L. Jong-Dae, A. Shimizu, and K. Yano Prothrombotic Activity Is Increased in Patients With Nonvalvular Atrial Fibrillation and Risk Factors for Embolism Chest, September 1, 2004; 126(3): 687 - 692. [Abstract] [Full Text] [PDF]

				R. Cote, C. Wolfson, S. Solymoss, A. Mackey, J. R Leclerc, D. Simard, F. Rouah, F. Bourque, and B. Leger Hemostatic Markers in Patients at Risk of Cerebral Ischemia Stroke, August 1, 2000; 31(8): 1856 - 1862. [Abstract] [Full Text] [PDF]

				J. P. Kistler and K. L. Furie Strategic Location of Large-Vessel Atherothrombotic Cerebral Vascular Disease Arch Neurol, November 1, 1999; 56(11): 1329 - 1330. [Full Text] [PDF]

				W. M. Feinberg, E. S. Cornell, S. D. Nightingale, L. A. Pearce, R. P. Tracy, R. G. Hart, and E. G. Bovill Relationship Between Prothrombin Activation Fragment F1.2 and International Normalized Ratio in Patients With Atrial Fibrillation Stroke, June 1, 1997; 28(6): 1101 - 1106. [Abstract] [Full Text]

				R. E. Peverill, R. W. Harper, J. Gelman, T. E. Gan, G. Harris, and J. J. Smolich Determinants of Increased Regional Left Atrial Coagulation Activity in Patients With Mitral Stenosis Circulation, August 1, 1996; 94(3): 331 - 339. [Abstract] [Full Text]

				T. Nagao, M. Hamamoto, A. Kanda, T. Tsuganesawa, M. Ueda, K. Kobayashi, T. Miyazaki, and A. Terashi Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation Stroke, August 1, 1995; 26(8): 1365 - 1368. [Abstract] [Full Text]

				J. P. Kistler The Risk of Embolic Stroke -- Another Piece of the Puzzle N. Engl. J. Med., December 1, 1994; 331(22): 1517 - 1519. [Full Text]